Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04567888 · ClinicalTrials.gov registry record · NA

Testing a Digital Intervention for Adolescents

A NA study, sponsored by Happify.

Completed
Registry status
NA
Development phase
353
Enrollment target

NCT04567888: Completed NA study, sponsored by Happify.

NCT04567888 is a NA study that has completed, run by Happify. The registered enrollment target is 353 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04567888, a NA study, has completed, sponsored by Happify.

COMPLETED
Registry status
NA
Development phase
353 participants
Enrollment target

Study Summary

Teen participants (ages 13-17) will be randomly assigned to either an experimental (the Happify Teens digital platform), or a waitlist control group. The study includes an 8-week intervention period and a 1-month follow up period.

Primary Outcome

10-item measure of perceived stress scoring how often the participant felt stressed by each statement in the following month from never (0) to very often (4). Scores can range from 0 to 40, with higher scores indicating higher levels of perceived stress.

Interventions

  • BEHAVIORAL Happify Teens

Trial Details

FieldValue
Enrollment Target 353 participants
Start Date 2021-06-03
Est. Completion 2022-04-11
Phase NA
Happify

6 total trials

What the finished NCT04567888 record still lists

NCT04567888 is an interventional study that assigns participants to a tested intervention. The registered 353 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower).

The record links to 0 conditions, and to 1 intervention - of which Happify Teens is the first listed.

NCT04567888 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04567888 about?

NCT04567888 is a clinical study titled "Testing a Digital Intervention for Adolescents". Teen participants (ages 13-17) will be randomly assigned to either an experimental (the Happify Teens digital platform), or a waitlist control group. The study includes an 8-week intervention period and a 1-month follow up period.

What is the current status of trial NCT04567888?

This trial is currently completed. It is a NA study. The enrollment target is 353 participants. The study started on 2021-06-03. Estimated completion is 2022-04-11.

What interventions are being tested in trial NCT04567888?

The interventions under investigation include: Happify Teens (BEHAVIORAL).

Who is sponsoring clinical trial NCT04567888?

This trial is sponsored by Happify, which has 6 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04567888's enrollment target sits among peer trials

353 292nd of 2000 higher than 1,709 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05548296 · 353 participants · Phase 2

    A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

  • NCT05884775 · 353 participants · NA

    Novel Digital Patient-Reported Outcomes Tool for Diabetes Management

  • NCT02579967 · 354 participants · Phase 2

    Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

  • NCT02610413 · 354 participants

    Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04567888, the US trial registry maintained by the National Library of Medicine. NCT04567888 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.